Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-99282 · 2 trials · 1 indication
Number of subjects with a DLT
The highest dose of CC-99282 in combination with obinutuzumab associated with acceptable safety and tolerability
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.
| Arm | Type | Description |
|---|---|---|
| CC-99282 + obinutuzumab | EXPERIMENTAL | Escalating doses of CC-99282 administered orally once daily on intermittent schedules with obinutuzumab IV infusion 1000 mg up to 2 years in Part A. CC-99282 administered orally once daily at MTD or alternative tolerating dosing schedule with obinutuzumab IV infusion 1000 mg up to 2 years in Part B. |
| Part A: Dose Escalation | EXPERIMENTAL | - |
| Part B: Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-99282 | DRUG | CC-99282 |
| Obinutuzumab | DRUG | Obinutuzumab |
| Rituximab | DRUG | Specified dose on specified days |
| Tafasitamab | DRUG | Specified dose on specified days |
| Valemetostat | DRUG | Specified dose on specified days |
Inclusion Criteria: 1. Subject is ≥18 years of age 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 3. Must have a documented diagnosis of CLL/SLL requiring treatment (IwCLL Guidelines for the Diagnosis and Treatment of CLL). In addition presence of clinically measurable dise...
CC-99282 is an investigational small molecule being studied for the treatment of relapsed or refractory non-Hodgkin lymphomas (R/R NHL). It is also being evaluated in combination with obinutuzumab for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The drug is in Phase 1 clinical development.
CC-99282 targets cereblon, a protein that is part of the ligase complex. By binding to cereblon, the drug modulates the ubiquitin-proteasome pathway, which can lead to the degradation of specific proteins involved in cancer cell growth. This mechanism is being explored in the treatment of non-Hodgkin lymphoma.
CC-99282 is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol BMY. The company is conducting clinical trials to evaluate the safety and preliminary efficacy of this investigational drug in patients with certain blood cancers.
CC-99282 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is studying the drug alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin lymphomas.
CC-99282 has been studied in two Phase 1 clinical trials. The first, NCT03930953, is an active but not recruiting study of the drug alone and in combination with anti-lymphoma agents in relapsed or refractory non-Hodgkin lymphomas. The second, NCT04434196, is a completed study of the drug combined with obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma.
CC-99282 is the primary name used for this investigational drug in clinical trials. No alternative names have been reported in the available clinical trial information. The drug is identified by its compound code CC-99282 in all related studies and publications.